

Resource Summary Report

Generated by [Kravitz](#) on Sep 19, 2026

NOD.Cg-Mcph1^{Tg(HLA-A2.1)}1Enge Prkdc Il2rg/SzJ

RRID:IMSR_JAX:009617

Type: Organism

Proper Citation

RRID:IMSR_JAX:009617

Organism Information

URL: <https://www.jax.org/strain/009617>

Proper Citation: RRID:IMSR_JAX:009617

Description: Mus musculus with name NOD.Cg-Mcph1^{Tg(HLA-A2.1)}1Enge Prkdc Il2rg/SzJ from IMSR.

Species: Mus musculus

Synonyms: NSG-A2. NOD scid gamma. HLA-A2.1. hu-NSG-A2. A2-NSG. NOD.Cg-Prkdc Il2rg Tg(HLA-A2.1)1Enge/SzJ

Notes: gene symbol note: protein kinase; DNA activated; catalytic polypeptide|microcephaly; primary autosomal recessive 1|interleukin 2 receptor; gamma chain|major histocompatibility complex; class I; A|major histocompatibility complex; class I; subtype A2.1; mutant strain|congenic strain: Prkdc|Mcph1|Il2rg|HLA-A|HLA-A2.1

Affected Gene: protein kinase; DNA activated; catalytic polypeptide|microcephaly; primary autosomal recessive 1|interleukin 2 receptor; gamma chain|major histocompatibility complex; class I; A|major histocompatibility complex; class I; subtype A2.1

Genomic Alteration: severe combined immunodeficiency|transgene insertion 1; Victor H Engelhard|targeted mutation 1; Warren J Leonard

Catalog Number: JAX:009617

Database: JAX Mice and Services

Database Abbreviation: JAX

Availability: live

Organism Name: NOD.Cg-Mcph1^{Tg(HLA-A2.1)}1Enge Prkdc Il2rg/SzJ

Record Creation Time: 20250513T053715+0000

Record Last Update: 20260919T054903+0000

Ratings and Alerts

No rating or validation information has been found for NOD.Cg-Mcph1^{Tg(HLA-A2.1)}1Enge Prkdc Il2rg/SzJ.

No alerts have been found for NOD.Cg-Mcph1^{Tg(HLA-A2.1)}1Enge Prkdc Il2rg/SzJ.

Data and Source Information

Source: [Integrated Animals](#)

Source Database: JAX Mice and Services

Usage and Citation Metrics

We found 14 mentions in open access literature.

Listed below are recent publications. The full list is available at [Kravitz](#) .

Kumar N, et al. (2026) Mechanistic insights and in vivo HIV suppression by the BRD4-targeting small molecule ZL0580. PLoS pathogens, 22(2), e1013449.

Wang Y, et al. (2025) Mutation of SMARCA4 Induces Cancer Cell-Intrinsic Defects in the Enhancer Landscape and Resistance to Immunotherapy. Cancer research, 85(11), 1997.

Boardman DA, et al. (2025) Armored human CAR Treg cells with PD1 promoter-driven IL-10 have enhanced suppressive function. Science advances, 11(24), eadx7845.

Seissler J, et al. (2025) Anti-CTLA-4 Treatment Abrogates Co-stimulation Blockade-induced Acceptance of Transgenic Porcine Islets in Humanized Mice. Transplantation, 109(12), e691.

Meraz IM, et al. (2025) NPRL2 gene therapy induces effective antitumor immunity in KRAS/STK11 mutant anti-PD1 resistant metastatic non-small cell lung cancer (NSCLC) in a humanized mouse model. eLife, 13.

Alomar FA, et al. (2025) Diastolic Dysfunction with Vascular Deficits in HIV-1-Infected Female Humanized Mice Treated with Antiretroviral Drugs. International journal of molecular sciences, 26(8).

Kim YM, et al. (2025) Generation of NOD SCID mice with near-complete deletions of Il2rg and Prkdc for human cancer and HSC engraftment. Transgenic research, 34(1), 35.

Steinkamp MP, et al. (2025) Clinical translation of TLR agonist-modified silicified cancer cell therapy supported by humanized mouse models. Molecular therapy. Oncology, 33(4), 201074.

Haderk F, et al. (2024) Focal adhesion kinase-YAP signaling axis drives drug-tolerant persister cells and residual disease in lung cancer. *Nature communications*, 15(1), 3741.

Xue G, et al. (2024) Clinical drug screening reveals clofazimine potentiates the efficacy while reducing the toxicity of anti-PD-1 and CTLA-4 immunotherapy. *Cancer cell*.

de Lima PO, et al. (2023) Development of an in vivo murine model of perineural invasion and spread of cutaneous squamous cell carcinoma of the head and neck. *Frontiers in oncology*, 13, 1231104.

Zeng B, et al. (2023) Skin-Grafting and Dendritic Cell "Boosted" Humanized Mouse Models Allow the Pre-Clinical Evaluation of Therapeutic Cancer Vaccines. *Cells*, 12(16).

Wang H, et al. (2021) Targeting EphA2 suppresses hepatocellular carcinoma initiation and progression by dual inhibition of JAK1/STAT3 and AKT signaling. *Cell reports*, 34(8), 108765.

Chew HY, et al. (2020) Endocytosis Inhibition in Humans to Improve Responses to ADCC-Mediating Antibodies. *Cell*, 180(5), 895.